Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
30 May 2022
Preliminary Final Report and Annual Report YE 31 March 2022
13 May 2022
Amplia Receives Second Ethics Clearance for Phase 2 Trial
12 May 2022
Amplia Presentation to 16th Bioshares Biotech Summit
09 May 2022
AMP945 Pre-IND Meeting Outcome
19 Apr 2022
Quarterly Activities and Cashflow Reports - March 2022 Qtr
06 Apr 2022
Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
05 Apr 2022
Notification of cessation of securities - ATX
17 Feb 2022
AMP945 Improves Survival in Human Pancreatic Cancer Model
15 Feb 2022
ATX Abstract accepted for presentation at Cancer Conference
14 Feb 2022
Sale of Unmarketable Parcels of Shares
Previous
1
2
3
4
5
6
Next
